Related Experiment Video
Updated: Nov 26, 2025

Isolation of Whole Cell Protein Lysates from Mouse Facial Processes and Cultured Palatal Mesenchyme Cells for Phosphoprotein Analysis
Published on: April 1, 2022
PTRH2: an adhesion regulated molecular switch at the nexus of life, death, and differentiation
Austin D Corpuz1,2, Joe W Ramos1, Michelle L Matter3
1Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, 96813, HI, USA.
Abstract:
Peptidyl-tRNA hydrolase 2 (PTRH2; Bit-1; Bit1) is an underappreciated regulator of adhesion signals and Bcl2 expression. Its key roles in muscle differentiation and integrin-mediated signaling are central to the pathology of a recently identified patient syndrome caused by a cluster of Ptrh2 gene mutations. These loss-of-function mutations were identified in patients presenting with severe deleterious phenotypes of the skeletal muscle, endocrine, and nervous systems resulting in a syndrome called Infantile-onset Multisystem Nervous, Endocrine, and Pancreatic Disease (IMNEPD). In contrast, in cancer PTRH2 is a potential oncogene that promotes malignancy and metastasis. PTRH2 modulates PI3K/AKT and ERK signaling in addition to Bcl2 expression and thereby regulates key cellular processes in response to adhesion including cell survival, growth, and differentiation. In this Review, we discuss the state of the science on this important cell survival, anoikis and differentiation regulator, and opportunities for further investigation and translation. We begin with a brief overview of the structure, regulation, and subcellular localization of PTRH2. We discuss the cluster of gene mutations thus far identified which cause developmental delays and multisystem disease. We then discuss the role of PTRH2 and adhesion in breast, lung, and esophageal cancers focusing on signaling pathways involved in cell survival, cell growth, and cell differentiation.
Insights
Peptidyl-tRNA hydrolase 2 (PTRH2) mutations cause Infantile-onset Multisystem Nervous, Endocrine, and Pancreatic Disease (IMNEPD). Conversely, PTRH2 promotes cancer malignancy and metastasis by regulating cell survival and differentiation signaling pathways.
Area of Science:
- Cellular Biology
- Molecular Biology
- Genetics
Background:
- Peptidyl-tRNA hydrolase 2 (PTRH2) regulates adhesion signals and Bcl2 expression, impacting muscle differentiation and integrin signaling.
- Loss-of-function mutations in PTRH2 cause Infantile-onset Multisystem Nervous, Endocrine, and Pancreatic Disease (IMNEPD), a severe genetic disorder.
- PTRH2 acts as an oncogene in cancer, promoting malignancy and metastasis.
Purpose of the Study:
- To review the current understanding of PTRH2's role in cell survival, anoikis, and differentiation.
- To discuss the implications of PTRH2 gene mutations in IMNEPD.
- To explore PTRH2's involvement in various cancers and associated signaling pathways.
Main Methods:
- Literature review of studies on PTRH2 structure, function, and disease association.
- Analysis of signaling pathways modulated by PTRH2, including PI3K/AKT and ERK.
- Examination of PTRH2's role in cell survival, growth, and differentiation in both disease and cancer contexts.
Main Results:
- PTRH2 mutations lead to severe skeletal muscle, endocrine, and nervous system defects.
- PTRH2 influences cell survival, growth, and differentiation through modulation of PI3K/AKT and ERK pathways.
- PTRH2 is implicated in the progression of breast, lung, and esophageal cancers.
Conclusions:
- PTRH2 is a critical regulator of cellular processes with dual roles in genetic disease and cancer.
- Further research into PTRH2 is warranted for potential therapeutic strategies.
- Understanding PTRH2's signaling network is key to addressing IMNEPD and cancer pathologies.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Receptor Tyrosine Kinases
Cell Polarization by Rho Proteins
TGF - β Signaling Pathway
Negative Regulator Molecules
The Ras Gene
Ras is a...

